• Results
  • Key Finding: Nearly half of companies with products on the...
Key Finding

Nearly half of companies with products on the market are involved in AMR surveillance

Curbing AMR depends on knowing which pathogens are developing resistance and where. The pharmaceutical industry can make an important contribution in this area, and many have publicly committed to supporting efforts to increase AMR surveillance. The Benchmark found that nine of the 19 companies reporting such efforts are running or supporting 19 AMR surveil­lance programmes across 147 countries. These are seven of the eight research-based companies in scope, one of the 10 generics companies, and 12 of the biopharmaceutical companies.

The activities are diverse in terms of scale, focus and duration. For instance, GSK periodically monitors interna­tional resistance trends in commu­nity acquired respiratory infections; Wockhardt collects data from a repre­sentative sample of the entire health­care infrastructure in India; and Pfizer’s ATLAS project tracks susceptibility and resistance patterns for a variety path­ogens and medicines across more than 60 countries.

Figure 13b. AMR surveillance programmes are being conducted in 147 countries worldwide.

Nine companies assessed by the Benchmark in this area are engaged in surveillance programmes, active in 75% of countries in the world.

Pneumonia gets the most attention, fol­lowed by other respiratory infections, including tuberculosis. Resistance is also being tracked in a variety of path­ogens considered a priority for moni­toring, including S. aureus, E. coli and H. influenzae. Some programmes track a single pathogen (e.g., Johnson & Johnson’s DREAM programme, focused on M. tuberculosis), while others moni­tor several pathogens and medicines in the same project (e.g., GSK’s SOAR and Merck & Co., Inc.’s SMART programmes).

Sharing the surveillance data with third-party initiatives that track AMR trends is a fundamental next step. At least eight companies reported their data are pre­sented at public conferences or pub­lished in journals, while two – Merck & Co., Inc. and Pfizer – publish their surveil­lance data on the Internet. GSK reported plans to publish all its surveillance data on the Internet and to collaborate with other organisations aiming to publish an online database conglomerating phar­maceutical industry AMR surveillance data.

Figure 13a. Nine out of 19 companies support AMR surveillance. 

The Benchmark found that nine of the 19 companies evaluated in this area are running or supporting 19 AMR surveillance programmes, spanning 147 countries.

Key challenges for ensuring that indus­try AMR surveillance efforts have maxi­mum impact include increasing involve­ment, harmonising data, converting prevalence studies into long-term mon­itoring programmes and increasing col­laboration with public health bodies coordinating surveillance.

For a full list of references, please see the 2018 AMR Benchmark report.

Learn more

View our detailed overview of each company’s performance